dministration of AMG 531 in both pre- and post-splenectomy ITP patients. Eligible patients had completed a previous AMG 531 study in ITP and had a baseline platelet count of less than 50,000 platelets per microliter, with no recent significant change in medical history. The AMG 531 starting dose was 1 g/kg by subcutaneous injection with dose adjustment to a maximum of 15 g/kg. Patients were administered AMG 531 by injection once weekly unless their platelet count exceeded 400,000 platelets per microliter. Once patients reached a stable dose and schedule, physician office visits were reduced from weekly to once per month. Concurrent corticosteroid treatment could be tapered when patients' platelet counts reached 50,000 platelets per microliter. The study is available for patients completing the two ongoing Phase 3 AMG 531 studies in ITP.

'"/>

Contact: Trish Hawkins
805-447-4587
Porter Novelli
12-Dec-2005

Page: 1 2 3
Related biology news :

1. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
2. Interim Aranesp data suggest major response in anemic patients with MDS
3. Interim data suggest major response with Aranesp(R) in anemic patients with MDS
4. Macho men are seen as bad choice for long-term love
5. DOE Joint Genome Institute secures long-term lease on production genomics facility
6. Cancer drug enhances long-term memory
7. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
8. New study sheds light on long-term effects of logging after wildfire
9. Common fungicide causes long-term changes in mating behavior
10. Prenatal exposure to glucocorticoids has long-term deleterious effects on newborns
11. Why is long-term therapy required to cure tuberculosis?